Roche awarded priority review status for Genmab drug rival
After a successful phase II/III study of its drug candidate mosunetuzumab, Roche has applied for marketing authorization from the FDA and been awarded priority review status.
by christian bundgaard, translated by catherine brett
Roche’s monoclonal antibody Lunsumio (mosunetuzumab) has taken a big step towards becoming the first approved treatment for non-Hodgkin lymphoma, a form of cancer.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
In a world of options, Genmab's CEO chose partnerships
For subscribers
